Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.53 USD

39.53
352,035

+0.08 (0.20%)

Updated Sep 23, 2024 11:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche Antiviral Drug Reduces Transmission in Late-stage Study

by Zacks Equity Research

Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected person to household members.

Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?

by Zacks Equity Research

The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.

Sweta Killa headshot

Tap the Weight-Loss Drug Market With These ETFs

by Sweta Killa

Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.

RHHBY or ABBV: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

RHHBY vs. ABBV: Which Stock Is the Better Value Option?

Regeneron, SNY Win FDA Approval for a Broader Dupixent Label

by Zacks Equity Research

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq

by Zacks Equity Research

The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.

Roche Stock to Benefit From Accu-Chek Smartguide Launch in Europe

by Zacks Equity Research

RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device may face tough competition from existing CGM devices.

Ahan Chakraborty headshot

Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks

by Ahan Chakraborty

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug

by Zacks Equity Research

RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.

Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals

by Zacks Equity Research

This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.

MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study

by Zacks Equity Research

Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.

The Zacks Analyst Blog Amazon, Roche, GE Aerospace, Canterbury Park and NVE

by Zacks Equity Research

Amazon, Roche, GE Aerospace, Canterbury Park and NVE are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Amazon.com, Roche & GE Aerospace

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Roche Holding AG (RHHBY) and GE Aerospace (GE), as well as two micro-cap stocks Canterbury Park Holding Corporation (CPHC) and NVE Corporation (NVEC).

Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug

by Zacks Equity Research

The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.

Affimed Appoints New CEO, Shares Fall on Leadership Change

by Zacks Equity Research

AFMD appoints Shawn M. Leland as the company's new chief executive officer. Stock falls on the news.

Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma

by Zacks Equity Research

MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.

SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others

by Zacks Equity Research

Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability progression.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs

by Kinjel Shah

LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.

Roche Obtains Approval For its Rare Blood Disorder Drug in the EU

by Zacks Equity Research

RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.

Here's Why You Should Consider Buying Akebia (AKBA) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.

J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa

by Zacks Equity Research

The approval of J&J's (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.

All You Need to Know About Roche Holding (RHHBY) Rating Upgrade to Strong Buy

by Zacks Equity Research

Roche Holding (RHHBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition

by Zacks Equity Research

Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.

Best Momentum Stocks to Buy for August 23rd

by Zacks Equity Research

APELY, RHHBY, and SBSI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 23, 2024.

New Strong Buy Stocks for August 23rd

by Zacks Equity Research

RHHBY, SBSI, FCCO, APELY and ARCT have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2024.